AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8029784
Drug: Melipramine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melipramine (3 x 2 coated tablet) given in 60‐mg daily doses
Trial: 3323258
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg at bedtime for four days prior to chloroquine administration)
Trial: 29402789
Drug: Hyoscine N-Butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine N-Butylbromide (20 mg)
Trial: 26797664
Drug: Self-administered computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered computer therapy for apraxia of speech
Trial: 22529257
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (ICT) with fluorouracil 800 mg/m(2)/d IV infusion on days 1-4 and 29-32, and cisplatin 80 mg/m(2) IV on days 1 and 29, followed by concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and standard-dose boost (SD) of 15 Gy.
Trial: 22529257
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (ICT) with fluorouracil and cisplatin, followed by concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and high-dose boost (HD) of 20-25 Gy.
Trial: 22529257
Drug: Concomitant radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and standard-dose boost (SD) of 15 Gy (reference arm).
Trial: 22529257
Drug: Concomitant radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant radiochemotherapy (RCT) with 45 Gy in 25 fractions over 5 weeks and high-dose boost (HD) of 20-25 Gy.
Trial: 22529257
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (ICT) effect comparison between groups A and B versus C and D.
Trial: 22529257
Drug: Radiation dose
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation dose effect comparison between groups A and C versus B and D.
Trial: 20534421
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEpo) - 3 consecutive intravenous doses (24,000 IU)
Trial: 17313499
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple eradication therapy (esomeprazole, clarithromycin, amoxicillin)
Trial: 17313499
Drug: Modified eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified eradication therapy (standard triple therapy plus bovine lactoferrin and probiotics)
Trial: 29673831
Drug: Hypovitaminosis D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypovitaminosis D defined as serum 25-hydroxyvitamin D concentration (25OHD) ≤30 ng/mL
Trial: 29673831
Drug: Hypovitaminosis D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypovitaminosis D ≤ 30 ng/mL
Trial: 27083763
Drug: Zinc plus
RxNorm normalized name: Zinc plus Copper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc plus multivitamins (20 mg elemental zinc, vitamin A 1000 IU, vitamin D 200 IU, B1 10 mg, B2 3 mg, B6 1 mg, B12 10 μg, nicotinamide 40 mg)
Trial: 24945737
Drug: silymarin (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: silymarin (420 mg/day)
Trial: 20739647
Drug: Sertraline (flexible-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (flexible-dose up to 200 mg)
Trial: 15232334
Drug: Nalmefene 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 5 mg
Trial: 15232334
Drug: Nalmefene 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene 40 mg
Trial: 11758326
Drug: Propofol (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1% propofol 20 ml with 2 ml of normal saline)
Trial: 7706597
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day sugar added to meals
Trial: 3580232
Drug: Sodium thiosulphate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium thiosulphate 10.6‐38.5 mg kg‐1
Trial: 23943468
Drug: Intermittent, CD4-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent, CD4-guided antiretroviral therapy (ART)
Trial: 9105355
Drug: Autogenous posterior
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autogenous posterior pharyngeal wall augmentation using a rolled superiorly based pharyngeal myomucosal flap
Trial: 9105355
Drug: Autogenous posterior
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autogenous posterior pharyngeal wall augmentation
Trial: 3991280
Drug: Furosemide, 2
RxNorm normalized name: Furosemide, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide, 2 mg/kg orally at diagnosis followed by 1 mg/kg 12 hours later if symptoms persisted
Trial: 28558139
Drug: Surfactant solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant solution
Trial: 24267864
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with levothyroxine (n=45; 61.6%)
Trial: 24267864
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with levothyroxine
Trial: 19726314
Drug: Tiopronin enteric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiopronin enteric capsules (200 mg)
Trial: 19726314
Drug: Tiopronin tablets
RxNorm normalized name: tiopronin Oral Tablet
DrugBank: Tiopronin (DB06823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiopronin tablets (200 mg)
Trial: 17416857
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel (wD)
Trial: 9626635
Drug: Oral risedronate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral risedronate, 30 mg/day for 84 days
Trial: 9626635
Drug: Oral risedronate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral risedronate, 30 mg/day for 84 days (repeated administration)
Trial: 7882703
Drug: Sustained-release ibuprofen
RxNorm normalized name: ibuprofen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release ibuprofen (1600 mg taken in the evening)
Trial: 7882703
Drug: Placebo (substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (substituted for a single dose of active treatment)
Trial: 2979246
Drug: Omeprazole 60
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 60 mg o.m.
Trial: 23577799
Drug: Flaxseed lignan
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed lignan (543 mg/day in BeneFlax)
Trial: 21323532
Drug: Cellular phone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellular phone reminder system (ARemind) - personalized text messages daily
Trial: 21323532
Drug: Beeper (BP)
RxNorm normalized name: Titanium Dioxide 0.38 g in 4.25 g TOPICAL POWDER [Purminerals 4 in 1 Makeup SPF 15 Deeper]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beeper (BP) - reminder beep at the time of dosing
Trial: 19175889
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 microg once daily (QD)
Trial: 14997197
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g PSK plus 300 mg UFT orally each day for 2 years
Trial: 14997197
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg UFT alone orally each day for 2 years
Trial: 14997197
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g PSK plus 300 mg UFT in stage III patients
Trial: 14997197
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg UFT alone in stage III patients
Trial: 20229169
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g PSK plus 300 mg UFT
Trial: 7780046
Drug: Stavudine 5
RxNorm normalized name: stavudine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 5 mg
Trial: 7780046
Drug: Stavudine 10
RxNorm normalized name: stavudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 10 mg
Trial: 7780046
Drug: Stavudine 20
RxNorm normalized name: stavudine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine 20 mg
Trial: 2083186
Drug: iproplatin (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iproplatin (240 mg/m2)
Trial: 2083186
Drug: cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin (100 mg/m2)
Trial: 2083186
Drug: carboplatin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carboplatin (300 mg/m2)
Trial: 40440
Drug: 50 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g/day of lecithin
Trial: 28260458
Drug: 450 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg/d valganciclovir
Trial: 28260458
Drug: 900 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg/d valganciclovir
Trial: 24727123
Drug: Simeprevir 100mg
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir 100mg once-daily with peginterferon α‐2a/ribavirin for 12 weeks then response-guided therapy with peginterferon α‐2a/ribavirin for 12 or 36 weeks
Trial: 24727123
Drug: Simeprevir 100mg
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir 100mg once-daily with peginterferon α‐2a/ribavirin
Trial: 18251154
Drug: Triple‐plus‐probiotics group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple‐plus‐probiotics group (1 week of PPI-based triple therapy + 8 weeks of probiotics)
Trial: 18251154
Drug: Triple‐only group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple‐only group (1 week of PPI-based triple therapy without probiotics)
Trial: 16340102
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of deep brain stimulation, pharmacotherapy, and rehabilitation training
Trial: 9787684
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol in frequent low doses (0.075 mg/kg every 30 minutes)
Trial: 9787684
Drug: Salbutamol in
RxNorm normalized name: Product containing salbutamol in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol in frequent low doses
Trial: 9787684
Drug: Salbutamol in
RxNorm normalized name: Product containing salbutamol in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol in hourly high doses (0.15 mg/kg every 60 minutes)
Trial: 7625415
Drug: Sublingual estradiol‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual estradiol‐17 beta (1 mg)
Trial: 31930464
Drug: Relationship characteristics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relationship characteristics (different ethnicity, poor socioeconomic status, difference in incomes, living in a rental property, alcohol and drug use, unprocessed previous history of physical violence)
Trial: 25404126
Drug: Intermittent Screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Screening and Treatment (IST) with artemether-lumefantrine (AL)
Trial: 25404126
Drug: Intermittent Preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Preventive Treatment (IPTp) with sulphadoxine-pyrimethamine (SP)
Trial: 21070457
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 24‐mg/mL cohesive gel and onabotulinumtoxinA
Trial: 12548091
Drug: Intravenous epoprostenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous epoprostenol
Trial: 9360182
Drug: Laminaria tents
RxNorm normalized name: Laminaria digitata preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laminaria tents + 4 mg PGE2 gel
Trial: 9360182
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel alone
Trial: 1548570
Drug: Dapsone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone (100 mg p.o. daily)
Trial: 1548570
Drug: Trimethoprim/sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulfamethoxazole (160 mg/800 mg p.o. daily)
Trial: 4033132
Drug: 0.23 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.23 g/kg alcohol
Trial: 4033132
Drug: 0.46 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.46 g/kg alcohol
Trial: 4033132
Drug: 0.12 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12 g/kg alcohol
Trial: 18164094
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine (0.15 U/kg)
Trial: 18164094
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro (0.15 U/kg)
Trial: 12892384
Drug: Magnesium-orotate (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium-orotate (3000 mg/day for 90 days)
Trial: 10756246
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of contrast agent at different rates (3 rates, 10 or 20 minutes duration).
Trial: 10756246
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of contrast agent.
Trial: 8650428
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil ethyl ester (Esapent, 5.1 g/day)
Trial: 1501052
Drug: Intravenous IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous IgM enriched immunoglobulin
Trial: 6593146
Drug: 0.2% neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% neutral solution of sodium fluoride, 10 ml, rinsed every second week during the school year
Trial: 29575737
Drug: Ultrasound-guided intraarticular
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided intraarticular glucocorticoid injections
Trial: 29575737
Drug: Palpation-guided intraarticular
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palpation-guided intraarticular glucocorticoid injections
Trial: 27561366
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without DTCP (Group A)
Trial: 25327602
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g of plant sterol esters a day (treatment group, n = 30)
Trial: 19758267
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g MMF plus low-dose tacrolimus
Trial: 19083666
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy (twice weekly from partners from 20 weeks gestation until the end of pregnancy)
Trial: 17217216
Drug: Pentoxifylline (400mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400mg 3 times daily, as coated, sustained release tablets)
Trial: 17217216
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug group (multivitamin and local heat therapy)
Trial: 14710168
Drug: Additional protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional protein group (n=73) received 48.2 g/day additional protein.
Trial: 9258974
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of baclofen
Trial: 9258974
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of baclofen
Trial: 8435362
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (EPI) 120 mg/m2 i.v. bolus injection divided over three days + Verapamil (VPL) 480 mg orally one day before and during EPI
Trial: 8435362
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (EPI) 120 mg/m2 i.v. bolus injection divided over three days without VPL
Trial: 3579676
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta administered intrathecally (IT)
Trial: 30328305
Drug: Fiber post
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber post placed in both buccal and palatal canals (Group 5)
Trial: 23364390
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 50 μg bid (FP100)
Trial: 23364390
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 250 μg bid (FP500)
Trial: 20385870
Drug: ST-246 250
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ST-246 250 mg/day
Trial: 20385870
Drug: ST-246 400
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ST-246 400 mg/day
Trial: 20385870
Drug: ST-246 800
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ST-246 800 mg/day
Trial: 6391928
Drug: Naproxen 1000
RxNorm normalized name: naproxen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 1000 mg in the morning, placebo in the evening
Trial: 6391928
Drug: Naproxen 1000
RxNorm normalized name: naproxen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 1000 mg in the evening, placebo in the morning
Trial: 6391928
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg in the morning and 500 mg in the evening
Trial: 31383465
Drug: Intraperitoneal antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal antibiotic irrigation (polymyxin B, 500,000 units/L)
Trial: 26149170
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg of bevacizumab
Trial: 26149170
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of ranibizumab
Trial: 20156032
Drug: P-OM3 4
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-OM3 4 g/day + simvastatin 40 mg/day
Trial: 20156032
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + simvastatin 40 mg/day
Trial: 15687321
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg L-000845704 once daily (qd)
Trial: 15687321
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg L-000845704 once daily (qd)
Trial: 15687321
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg L-000845704 twice daily (bid)
Trial: 15687321
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of L-000845704
Trial: 2025770
Drug: Compression applied
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compression applied immediately after injection
Trial: 6093528
Drug: Ceftriaxone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (single dose of 250 mg)
Trial: 31314045
Drug: iFR-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iFR-guided treatment
Trial: 31314045
Drug: FFR-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFR-guided treatment
Trial: 27114196
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg, adjustable to 25 mg or 100 mg based on efficacy and safety)
Trial: 22645995
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg estriol as vaginal cream
Trial: 20653966
Drug: Peer-led education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-led education (weekly educational programs for one month)